 Jacob Houghton
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Positron-Emission Tomography | 12 | 2022 | 343 | 2.170 |
Why?
| | Immunoconjugates | 5 | 2024 | 138 | 1.480 |
Why?
| | Radiopharmaceuticals | 8 | 2024 | 205 | 1.320 |
Why?
| | Zirconium | 4 | 2018 | 12 | 1.300 |
Why?
| | Radioisotopes | 4 | 2018 | 37 | 1.300 |
Why?
| | Radioimmunotherapy | 3 | 2021 | 25 | 1.210 |
Why?
| | CA-19-9 Antigen | 3 | 2018 | 34 | 1.090 |
Why?
| | Pancreatic Neoplasms | 7 | 2020 | 928 | 1.060 |
Why?
| | Metallocenes | 2 | 2022 | 2 | 0.870 |
Why?
| | Copper Radioisotopes | 2 | 2022 | 4 | 0.850 |
Why?
| | Adamantane | 1 | 2023 | 18 | 0.770 |
Why?
| | Tissue Distribution | 7 | 2023 | 335 | 0.710 |
Why?
| | Macrocyclic Compounds | 2 | 2021 | 15 | 0.710 |
Why?
| | Ferrous Compounds | 1 | 2021 | 25 | 0.680 |
Why?
| | Acetyltransferases | 4 | 2013 | 27 | 0.660 |
Why?
| | Bacterial Proteins | 4 | 2013 | 967 | 0.590 |
Why?
| | Antibodies, Monoclonal | 4 | 2022 | 1505 | 0.560 |
Why?
| | Mice, Nude | 6 | 2021 | 679 | 0.550 |
Why?
| | Click Chemistry | 2 | 2016 | 54 | 0.500 |
Why?
| | Cell Line, Tumor | 8 | 2022 | 3542 | 0.490 |
Why?
| | Prostatic Neoplasms | 2 | 2021 | 978 | 0.480 |
Why?
| | Aminoglycosides | 3 | 2010 | 30 | 0.470 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 34 | 0.460 |
Why?
| | Multimodal Imaging | 2 | 2016 | 129 | 0.460 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2015 | 70 | 0.450 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2018 | 258 | 0.450 |
Why?
| | Antigens, Bacterial | 2 | 2012 | 126 | 0.440 |
Why?
| | Mycobacterium smegmatis | 2 | 2012 | 14 | 0.400 |
Why?
| | Antigens, Neoplasm | 1 | 2015 | 271 | 0.400 |
Why?
| | Mycobacterium tuberculosis | 3 | 2013 | 318 | 0.390 |
Why?
| | Capreomycin | 1 | 2012 | 3 | 0.380 |
Why?
| | Models, Biological | 1 | 2018 | 1764 | 0.330 |
Why?
| | Antitubercular Agents | 1 | 2012 | 208 | 0.320 |
Why?
| | Mice | 12 | 2023 | 18329 | 0.320 |
Why?
| | Animals | 15 | 2023 | 38030 | 0.310 |
Why?
| | Molecular Imaging | 3 | 2016 | 57 | 0.240 |
Why?
| | Deferoxamine | 2 | 2015 | 27 | 0.230 |
Why?
| | Acetylation | 4 | 2013 | 259 | 0.220 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2214 | 0.220 |
Why?
| | Molecular Structure | 2 | 2016 | 486 | 0.220 |
Why?
| | Microscopy, Fluorescence | 2 | 2016 | 408 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2018 | 934 | 0.210 |
Why?
| | Antibodies | 2 | 2024 | 397 | 0.210 |
Why?
| | Heterografts | 1 | 2023 | 143 | 0.180 |
Why?
| | Drug Resistance, Bacterial | 3 | 2013 | 185 | 0.180 |
Why?
| | Metal Nanoparticles | 1 | 2023 | 80 | 0.180 |
Why?
| | Radioimmunodetection | 1 | 2021 | 2 | 0.170 |
Why?
| | Carcinoembryonic Antigen | 1 | 2021 | 40 | 0.170 |
Why?
| | Humans | 16 | 2023 | 145475 | 0.160 |
Why?
| | Anti-Bacterial Agents | 4 | 2013 | 1923 | 0.160 |
Why?
| | Gastritis, Hypertrophic | 1 | 2019 | 4 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2020 | 76 | 0.150 |
Why?
| | Autoradiography | 1 | 2018 | 66 | 0.140 |
Why?
| | Serum | 1 | 2018 | 58 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2019 | 4560 | 0.130 |
Why?
| | Colonic Neoplasms | 1 | 2019 | 257 | 0.130 |
Why?
| | Kanamycin | 2 | 2013 | 10 | 0.120 |
Why?
| | Antibodies, Neutralizing | 1 | 2019 | 340 | 0.120 |
Why?
| | Receptors, Bombesin | 1 | 2016 | 5 | 0.120 |
Why?
| | Gallium Radioisotopes | 1 | 2016 | 16 | 0.120 |
Why?
| | Nanoparticles | 1 | 2023 | 517 | 0.120 |
Why?
| | Radiometry | 1 | 2016 | 56 | 0.120 |
Why?
| | ErbB Receptors | 1 | 2019 | 635 | 0.120 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2020 | 293 | 0.120 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2015 | 6 | 0.120 |
Why?
| | Cyclooctanes | 1 | 2015 | 6 | 0.120 |
Why?
| | Fluorine Radioisotopes | 1 | 2015 | 14 | 0.120 |
Why?
| | Catalytic Domain | 2 | 2013 | 234 | 0.110 |
Why?
| | Transplantation, Heterologous | 1 | 2015 | 170 | 0.110 |
Why?
| | Tumor Burden | 1 | 2016 | 325 | 0.110 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 246 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1997 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 881 | 0.100 |
Why?
| | Chemistry, Inorganic | 1 | 2013 | 1 | 0.100 |
Why?
| | Radiation Dosage | 1 | 2015 | 193 | 0.100 |
Why?
| | Coenzyme A | 1 | 2013 | 8 | 0.100 |
Why?
| | Fluorescent Dyes | 1 | 2015 | 333 | 0.100 |
Why?
| | Amikacin | 1 | 2013 | 29 | 0.100 |
Why?
| | Stereoisomerism | 1 | 2013 | 103 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 992 | 0.100 |
Why?
| | Tobramycin | 1 | 2013 | 63 | 0.100 |
Why?
| | Binding Sites | 2 | 2013 | 1310 | 0.100 |
Why?
| | Anabaena variabilis | 1 | 2012 | 1 | 0.100 |
Why?
| | ATP Citrate (pro-S)-Lyase | 1 | 2012 | 4 | 0.100 |
Why?
| | Dicarboxylic Acids | 1 | 2012 | 12 | 0.090 |
Why?
| | Carbohydrate Metabolism | 1 | 2012 | 59 | 0.090 |
Why?
| | Chloramphenicol | 1 | 2012 | 11 | 0.090 |
Why?
| | Chloramphenicol O-Acetyltransferase | 1 | 2012 | 35 | 0.090 |
Why?
| | Crystallography, X-Ray | 1 | 2013 | 486 | 0.090 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 649 | 0.090 |
Why?
| | Molecular Dynamics Simulation | 1 | 2013 | 265 | 0.080 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 192 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3413 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2012 | 204 | 0.080 |
Why?
| | Nucleotidyltransferases | 1 | 2010 | 29 | 0.080 |
Why?
| | Substrate Specificity | 4 | 2012 | 387 | 0.080 |
Why?
| | Drug Resistance, Microbial | 1 | 2010 | 64 | 0.080 |
Why?
| | Protein Binding | 2 | 2013 | 2238 | 0.080 |
Why?
| | Acyl Coenzyme A | 1 | 2010 | 32 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 627 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 439 | 0.070 |
Why?
| | Chelating Agents | 2 | 2024 | 76 | 0.070 |
Why?
| | Fatty Acids | 1 | 2012 | 457 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 820 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2012 | 529 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2015 | 1131 | 0.070 |
Why?
| | Mice, Knockout | 1 | 2015 | 3124 | 0.070 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2010 | 507 | 0.070 |
Why?
| | Escherichia coli | 1 | 2012 | 835 | 0.070 |
Why?
| | Male | 4 | 2023 | 72843 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2010 | 451 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2906 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2010 | 769 | 0.050 |
Why?
| | Gold | 1 | 2023 | 116 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2012 | 362 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2012 | 762 | 0.040 |
Why?
| | Azoxymethane | 1 | 2019 | 18 | 0.040 |
Why?
| | Amino Acids | 1 | 2024 | 519 | 0.040 |
Why?
| | Dextran Sulfate | 1 | 2019 | 93 | 0.040 |
Why?
| | Female | 3 | 2017 | 78845 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.040 |
Why?
| | Carcinogens | 1 | 2019 | 123 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2019 | 277 | 0.040 |
Why?
| | Hepatocytes | 1 | 2019 | 224 | 0.030 |
Why?
| | Biomarkers, Tumor | 2 | 2016 | 1321 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2012 | 2129 | 0.030 |
Why?
| | Kinetics | 2 | 2012 | 1567 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2016 | 115 | 0.030 |
Why?
| | Isotope Labeling | 1 | 2016 | 82 | 0.030 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 2015 | 8 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 309 | 0.030 |
Why?
| | Cycloaddition Reaction | 1 | 2015 | 31 | 0.030 |
Why?
| | Stromal Cells | 1 | 2015 | 121 | 0.030 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2015 | 81 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2019 | 2188 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 981 | 0.020 |
Why?
| | Pancreas | 1 | 2015 | 341 | 0.020 |
Why?
| | Sterols | 1 | 2012 | 20 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2012 | 73 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 852 | 0.020 |
Why?
| | Fusidic Acid | 1 | 2012 | 1 | 0.020 |
Why?
| | Cricetinae | 1 | 2012 | 305 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4148 | 0.020 |
Why?
| | X-Ray Diffraction | 1 | 2012 | 83 | 0.020 |
Why?
| | Glucagon | 1 | 2012 | 114 | 0.020 |
Why?
| | Crystallization | 1 | 2012 | 136 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 665 | 0.020 |
Why?
| | Protein Interaction Mapping | 1 | 2012 | 105 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 229 | 0.020 |
Why?
| | Dyslipidemias | 1 | 2012 | 184 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 381 | 0.020 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 49 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 485 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2015 | 874 | 0.020 |
Why?
| | Phylogeny | 1 | 2012 | 917 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2883 | 0.020 |
Why?
| | Computer Simulation | 1 | 2012 | 1003 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1598 | 0.020 |
Why?
| | Glucose | 1 | 2012 | 1048 | 0.020 |
Why?
| | Calcium | 1 | 2012 | 1190 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2012 | 935 | 0.020 |
Why?
| | Diet | 1 | 2012 | 1277 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5584 | 0.010 |
Why?
| | Liver | 1 | 2012 | 1896 | 0.010 |
Why?
| | Biomarkers | 1 | 2012 | 4295 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5216 | 0.010 |
Why?
| | Obesity | 1 | 2012 | 3116 | 0.010 |
Why?
|
|
Houghton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|